logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
S

Shai Mulinari

Lund University

24H指数
120论文数
1.8K被引数
收录论文 39
发表时间
logo
Over-represented as volunteers, under-represented as patients: racial and ethnic inequalities in a large sample of U.S. phase 1 clinical trials志愿者中占比过高，患者中占比过低：美国大型I期临床试验中的种族和民族不平等
errCritical Public Health
IF2.3
err2026-05-15
err0
errOAAI
errShai Mulinari; Fabio Schreiber; Ingeborg Sundby Ulsnes; Anna Bredström; Jill A. Fisher
err分享
err收藏
Pharmaceutical company promotional payments to English general practices: a longitudinal study制药公司对英国全科诊所的促销付款：一项纵向研究
errBJGP Open
IF2
err2026-04-01
err0
PREAI
errMulinari, Shai; Malik, Minahil; Larkin, James; Elsharkawy, Mostafa; Fahey, Tom; Moriarty, Frank; Ozieranski, Piotr
err分享
err收藏
Unknowns of drug company payment disclosure: why the UK needs payment transparency legislation药品公司付款披露的不确定性：为何英国需要付款透明度立法
errBMJ EVIDENCE-BASED MEDICINE
IF7.6
err2025-01-07
err0
PREAI
errOzieranski, P; Rickard, E; Mulinari, S
err分享
err收藏
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015 and 2019: A content analysis英国制药行业支付透明度数据库2015年和2019中用于报告的制药公司方法: 内容分析
errHEALTH POLICY
IF3.4
err2024-11-01
err0
errOAAI
errLarkin, James; Matthes, Britta; Azribi, Mohamed; Kearns, Conor; Mulinari, Shai; Rickard, Emily; Moriarty, Frank; Fahey, Tom; Ozieranski, Piotr
err分享
err收藏
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
errBMJ-BRITISH MEDICAL JOURNAL
IF42.7
err2024-07-12
err1
PREAI
errOzieranski, Piotr; Mulinari, Shai
err分享
err收藏
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals
errCTS-CLINICAL AND TRANSLATIONAL SCIENCE
IF2.8
err2024-07-10
err2
errOAAI
errHakariya, Hayase; Moriarty, Frank; Ozaki, Akihiko; Mulinari, Shai; Saito, Hiroaki; Tanimoto, Tetsuya
err分享
err收藏
Patterns of company misconduct, recidivism, and complaint resolution delays: A temporal analysis of UK pharmaceutical industry self-regulation within the European context
errREGULATION & GOVERNANCE
IF3.8
err2024-06-20
err3
errOAAI
errMulinari, Shai; Pashley, Dylan; Ozieranski, Piotr
err分享
err收藏
Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval
errQJM-AN INTERNATIONAL JOURNAL OF MEDICINE
IF6.4
err2024-06-12
err1
PREAI
errHakariya, H.; Ozaki, A.; Mulinari, S.; Moriarty, F.; Tanimoto, T.
err分享
err收藏
Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019: An observational study欧洲医疗器械行业报告的向医疗机构支付2017年2019年: 一项观察性研究
errhealth policy
IF3.7
err2024-06-01
err5
errOAAI
errLarkin, James; Mulinari, Shai; Ozieranski, Piotr; Lynch, Kevin; Fahey, Tom; Ozaki, Akihiko; Moriarty, Frank
err分享
err收藏
Delays in dealing with complaints against drug companies are growing, BMJ finds
errBMJ-BRITISH MEDICAL JOURNAL
IF42.7
err2024-02-14
err2
errOAAI
errBoytchev, Hristio; Mulinari, Shai; Ozieranski, Piotr
err分享
err收藏
Unethical pharmaceutical marketing: a common problem requiring collective responsibility
errBMJ-BRITISH MEDICAL JOURNAL
IF42.7
err2023-09-19
err8
errOAAI
errMulinari, Shai; Ozieranski, Piotr
err分享
err收藏
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
errGLOBALIZATION AND HEALTH
IF4.5
err2023-03-03
err16
errOAAI
errOzieranski, Piotr; Saito, Hiroaki; Rickard, Emily; Mulinari, Shai; Ozaki, Akihiko
err分享
err收藏
Short-circuiting biology: Digital phenotypes, digital biomarkers, and shifting gazes in psychiatry
errBIG DATA & SOCIETY
IF5.9
err2023-01-12
err4
errOAAI
errMulinari, Shai
err分享
err收藏
Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
errHEALTH POLICY
IF3.4
err2022-12-01
err3
errOAAI
errMulinari, Shai; Pashley, Dylan; Ozieranski, Piotr
err分享
err收藏
Tip of The Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe
errINTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT
IF5.1
err2022-03-15
err12
errOAAI
errOzieranski, Piotr; Martinon, Luc; Jachiet, Pierre-Alain; Mulinari, Shai
err分享
err收藏
Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
errINTERNATIONAL JOURNAL OF HEALTH SERVICES
IF3.1
err2022-03-01
err8
errOAAI
errPashley, Dylan; Ozieranski, Piotr; Mulinari, Shai
err分享
err收藏
Capitalizing on transparency: Commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act利用透明度: 《医师阳光法案》后的商业监督和药品营销
errBIG DATA & SOCIETY
IF5.9
err2022-02-09
err14
errOAAI
errMulinari, Shai; Ozieranski, Piotr
err分享
err收藏
Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries
errHEALTH POLICY
IF3.4
err2021-07-01
err24
errOAAI
errMulinari, Shai; Martinon, Luc; Jachiet, Pierre-Alain; Ozieranski, Piotr
err分享
err收藏
Is there evidence for the racialization of pharmaceutical regulation? Systematic comparison of new drugs approved over five years in the USA and the EU
errSOCIAL SCIENCE & MEDICINE
IF5
err2021-07-01
err9
errOAAI
errMulinari, Shai; Vilhelmsson, Andreas; Ozieranski, Piotr; Bredstrom, Anna
err分享
err收藏
Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
errHEALTH POLICY
IF3.4
err2019-12-01
err21
errOAAI
errRickard, Emily; Ozieranski, Piotr; Mulinari, Shai
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
S
S. V. Subramanian
H 指数: 110 · 论文数: 858
T
Tom Fahey
H 指数: 76 · 论文数: 586
J
Juan Merlo
H 指数: 63 · 论文数: 317
K
Kristina Johnell
H 指数: 53 · 论文数: 253
K
Kevin Lynch
H 指数: 50 · 论文数: 471
查看更多